- Medibank Private‘s full-year revenue was reported at A$8.60 billion, closely matching the estimated A$8.62 billion.
- The company achieved a net income of A$500.8 million.
- A final dividend of A$0.1020 per share was declared.
- Net investment income amounted to A$207.8 million.
- The underlying profit stood at A$618.7 million.
- Analyst recommendations include 2 buy ratings, 8 hold ratings, and 2 sell ratings.
A look at Medibank Private Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 3 | |
| Growth | 3 | |
| Resilience | 4 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Medibank Private, a provider of private health care coverage in Australia, has received a solid overall outlook based on Smartkarma Smart Scores. With a strong score in Resilience and Momentum, the company is positioned well for long-term growth and stability. The Resilience score indicates the company’s ability to weather challenges, while the Momentum score suggests positive market momentum in its favor.
Additionally, Medibank Private scores well in Dividend and Growth, further underlining its potential for sustained performance. While the Value score is moderate, the company’s strengths in other areas contribute to a favorable long-term outlook. Overall, Medibank Private appears poised to continue providing quality health insurance products and services to its customers across Australia.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
